Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.8K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.8K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

83.2K
Overview
83.2K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

788
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
788
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.7K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.7K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.5K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hematopoietic Stem Cell Transplant and Brain Volume Changes in Adults With Sickle Cell Disease.

Neurology·2026
Same author

Clonal dynamics, tolerance, and adverse events after CD45-ADC-conditioned autologous HSPC transplantation in macaques.

Blood advances·2026
Same author

Fetal Hemoglobin Research and Clinical Relevance in Sickle Cell Disease.

Physiology (Bethesda, Md.)·2025
Same author

Comparative analysis of CRISPR-Cas9, lentiviral transduction, and base editing for sickle cell disease in a murine model.

Blood advances·2025
Same author

Nonclinical evaluation of renizgamglogene autogedtemcel for SCD and TDT.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same author

Hematopoietic stem cell therapy with gene modification to treat sickle cell disease.

Stem cells translational medicine·2025

Related Experiment Video

Updated: Jan 3, 2026

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
08:32

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

4.2K

Immunoresponse to Gene-Modified Hematopoietic Stem Cells.

Claire M Drysdale1, John F Tisdale1, Naoya Uchida1

  • 1Cellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institute (NHLBI) /National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USA.

Molecular Therapy. Methods & Clinical Development
|November 26, 2019
PubMed
Summary

Hematopoietic stem cell (HSC) gene therapy faces immune rejection challenges. Conditioning regimens like total body irradiation (TBI) improve engraftment and tolerance, guiding therapy design for genetic disorders.

Keywords:
conditioninggene therapyhematopoietic stem cellsimmunoresponse

More Related Videos

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.6K
Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells
11:16

Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells

Published on: February 15, 2019

8.0K

Related Experiment Videos

Last Updated: Jan 3, 2026

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
08:32

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

4.2K
Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.6K
Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells
11:16

Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells

Published on: February 15, 2019

8.0K

Area of Science:

  • Hematology
  • Immunology
  • Gene Therapy

Background:

  • Hematopoietic stem cell (HSC) gene therapy offers potential cures for genetic disorders.
  • Immunological rejection of transgene products can limit the efficacy of gene-modified HSCs.

Purpose of the Study:

  • To review conditioning and immunosuppression strategies for HSC-targeted gene therapy and gene editing.
  • To address immune concerns associated with novel gene therapy techniques.

Main Methods:

  • Review of preclinical and clinical data on HSC engraftment and tolerance.
  • Analysis of conditioning regimens including total body irradiation (TBI) and chemotherapy.
  • Evaluation of immune responses to transgene products.

Main Results:

  • Myeloablative TBI promotes efficient engraftment and tolerance to gene-modified HSCs.
  • Chemotherapy alone is insufficient for tolerance to immunogenic transgene products.
  • Xenogenic or absent proteins may necessitate additional immunosuppression.

Conclusions:

  • Conditioning strategies are crucial for successful HSC gene therapy.
  • Careful consideration of conditioning and immunosuppression is needed for gene editing and in vivo gene therapy.
  • Optimizing immune tolerance is key to advancing HSC gene therapy.